Home > Neurology > ECTRIMS 2021 > Treatment Trials and Strategies > Long-term suppression of MRI disease activity with ocrelizumab

Long-term suppression of MRI disease activity with ocrelizumab

Presented By
Dr Douglas Arnold, McGill University, Canada
Conference
ECTRIMS 2021
Trial
Phase 3, OPERA I/II, ORATORIO
Patients receiving ocrelizumab maintained near complete suppression of focal MRI disease activity. Advantages were gained both in patients receiving continuous ocrelizumab and in those who switched to ocrelizumab later. Specifically, both relapsing MS (RMS) and primary progressive MS (PPMS) patients showed a reduction of T2 and T1 lesion volume accumulation as well as reduced global/regional volume loss at the 5th year of follow-up [1]. In the original, phase 3 OPERA I/II (NCT01247324; NCT01412333) and ORATORIO (NCT01194570) trials, the efficacy and safety of ocrelizumab versus interferon beta-1a (IFN) in RMS and versus placebo in PPMS were demonstrated [2]. In the open-l...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on